Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Sees Increased Sales, Widened Loss in Q4

NEW YORK, Feb.21 - Visible Genetics on Thursday reported a modest increase in revenue and net loss in the fourth quarter as a bump in the sale of its consumables and sequencing systems balanced greater R&D spending.

 

In the period ended Dec. 31, Visible Genetics said sales reached $3.2 million compared with $3.0 million one year ago. The changes was helped along by sales of the company's GeneKit tools and consumables, which reached $2.6 million in the quarter compared with $2.4 million year over year. Sales of its sequencing systems remained flat at $600,000, Visible Genetics said.

 

R&D spending in the quarter inched up to $2.9 million from $2.7 in the year-ago period. Net loss came in at $11.9 million, or $.71 per share, compared with $10.4 million, or $.65 per shares year over year, the company said.

 

Visible Genetics also reported that cash and short-term investments as of Dec. 31 was $53.2 million, a significant drop from the $80.4 million it had one year ago.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.